/* RM 168662 - Track viewing of recorded presentations */

The Autism Biomarkers Consortium for Clinical Trials: Eye Tracking Interim Analyses

F. Shic1, A. Naples2, E. Barney1, C. Sugar3, M. Murias4, J. Dziura5, C. Brandt6, R. A. Bernier7, K. Chawarska8, G. Dawson9, S. Faja10, S. Jeste11, C. A. Nelson12, S. J. Webb13 and J. C. McPartland2, (1)Center for Child Health, Behavior and Development, Seattle Children's Research Institute, Seattle, WA, (2)Yale Child Study Center, Yale University School of Medicine, New Haven, CT, (3)Department of Biostatistics, UCLA, Los Angeles, CA, (4)Duke Center for Autism and Brain Development, Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, (5)Emergency Medicine, Yale School of Medicine, New Haven, CT, (6)Yale University, New Haven, CT, (7)Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, (8)Child Study Center, Yale University School of Medicine, New Haven, CT, (9)Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, (10)Division of Developmental Medicine, Boston Children's Hospital / Harvard Medical School, Brookline, MA, (11)Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA, (12)Department of Developmental Medicine, Boston Children's Hospital, Boston, MA, (13)Center, Seattle Children’s Research Institute & University of Washington, Seattle, WA